BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments
“We are very excited to be working with Bloom Burton, Canada’s leading healthcare investment banking firm,” said Ahmad Doroudian, CEO of BetterLife.
- “We are very excited to be working with Bloom Burton, Canada’s leading healthcare investment banking firm,” said Ahmad Doroudian, CEO of BetterLife.
- Development of scaled-up (kg batch size) manufacturing of BetterLife’s proprietary form of 2-bromo-LSD (“BETR-001”) using BetterLife’s proprietary synthetic pathway.
- The starting material and whole synthetic pathway do not involve any controlled substance and, therefore, are not bound by controlled substance regulations.
- Scientific presentations on BETR-001 preclinical data were made at the following conferences:
Canadian Association for Neuroscience (CAN) / May 12-15, 2022 / Toronto, Canada.